



Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats

July 16, 2020

SOUTH SAN FRANCISCO, Calif. & BOSTON, Mass.--(BUSINESS WIRE)--Jul. 16, 2020-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced a partnership for the engineering and optimization of novel antibodies for the treatment of serious diseases in dogs and cats.

"Many diseases in animals manifest through the same protein targets observed in humans," said Juergen Horn, PhD, chief executive officer of Invetx. "By partnering with Twist to create specific antibody libraries for veterinary species, we are expanding Invetx's ability to deliver best-in-class antibody therapeutics and translate biotechnology approaches already proven successful in the human field to veterinary medicine."

Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will use its Twist Antibody Optimization (TAO) platform to engineer and optimize multiple antibodies against important disease targets in animal health. The Twist technology will be a key component of Invetx's antibody discovery effort and the company's strategy to develop safer and more effective veterinary medicines.

"Leading market research firms estimate the global animal medicines market was nearly \$34 billion in 2019, with a compound annual growth rate of five to seven percent," said Emily M. Leproust, PhD, chief executive officer and co-founder of Twist Bioscience. "With the high degree of genetic conservation between species, we believe Invetx's approach to bring the best of biopharma to animal health has incredible possibilities to offer improved therapeutics to our pets. We look forward to being an integral part of Invetx's effort to revolutionize the medicines available to the animal health industry."

About Invetx

Invetx is building the world's premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. In February 2020, the company announced a \$15 million Series A financing and strategic partnerships with AbCellera, a biotech company specializing in antibody discovery located in Vancouver, BC and WuXi Biologics, a global company with leading biologics technology platforms. Invetx is a private company headquartered in Boston, Massachusetts. For more information, see invetx.com.

About Twist Bioscience

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including diagnostics, therapeutics, industrial chemicals, agriculture and academic research. For more information visit www.twistbioscience.com and www.twistbiopharma.com.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability of the TAO platform to successfully assist in the engineering and optimization of multiple antibodies against important disease targets in animal health and the estimated compound growth rate of five to seven percent for global animal medicines, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk of breach of Twist's security measures, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission dated May 13, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVETX CONTACTS:

Partners and Investors:

Juergen Horn, PhD
Chief Executive Officer
juergen.horn@invetx.com

Media:

Susan Kinkead
415-509-3610
susan@kinkeadcomm.com

TWIST BIOSCIENCE CONTACTS:

Investors:

Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Media:

Angela Bitting
925- 202-6211
media@twistbioscience.com

Source: Twist Bioscience Corporation